PTC Therapeutics, Inc. vs Evotec SE: Examining Key Revenue Metrics

Biotech Giants' Revenue Growth: A Decade in Review

__timestamp	Evotec SE	PTC Therapeutics, Inc.
Wednesday, January 1, 2014	89496000	22963000
Thursday, January 1, 2015	127677000	36766000
Friday, January 1, 2016	164507000	82705000
Sunday, January 1, 2017	257630000	194392000
Monday, January 1, 2018	375405000	264734000
Tuesday, January 1, 2019	446437000	306980000
Wednesday, January 1, 2020	500924000	380766000
Friday, January 1, 2021	618034000	538593000
Saturday, January 1, 2022	751448000	698801000
Sunday, January 1, 2023	781426000	937822000

Unleashing the power of data

PTC Therapeutics, Inc. vs Evotec SE: A Revenue Race

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success. Over the past decade, PTC Therapeutics, Inc. and Evotec SE have been at the forefront of this race. Since 2014, Evotec SE has seen its revenue grow by an impressive 773%, starting from a modest $89 million to a robust $781 million in 2023. Meanwhile, PTC Therapeutics, Inc. has not lagged far behind, with its revenue surging by an astounding 3,984%, from $23 million to $938 million over the same period.

This remarkable growth highlights the increasing demand for innovative therapies and the strategic prowess of these companies. As we look to the future, the competition between these two giants will undoubtedly continue to shape the landscape of the biotech industry.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025